MC38-B2m KO

Export PDF

Strain Information

Cell Line

MC38-B2mem1Smoc

Cat. NO.

NMC-230048

Model Description

B2m gene knockout MC38 cell line

Strain State

Validation of tumorigenic capacity completed

Validation Data

1.png

Fig1. Detection of B2M expression on in vitro cultured cells of MC38-B2M-KO cell line by FACS. 

2.png

Fig2. Detection of B2M expression on in vitro cultured cells of MC38-B2M-KO cell line by WB. 

3.png

Fig3. In vivo validation of MC38-B2M-KO cells in C57BL/6 mice (n=6).

C57BL/6 mice were inoculated with MC38-B2M-KO subcutaneously at 1×106 cells/mouse inoculum for tumor development.

4.png

Fig4. B2M expression in tumors after in vivo growth of MC38-B2M-KO in wild type C57BL/6 mice

The tumors were collected at day 18 post tumor cell inoculation.

You may also like

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

Learn more
Customizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!

At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.

Learn more